Angiotensin Converting Enzyme (ACE) Inhibitors Market by Types (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, and Phosphonate-containing Agents), Applications (Hypertension, Cardiovascular Diseases, Kidney Diseases, and Others), and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa)- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global angiotensin converting enzymes (ACE) inhibitors market size was around USD 11,693 million in 2020 and is projected to register a CAGR of 3.1%, during the forecast period, 2021-2028. The growth of the market is attributed to rising prevalence of cardiovascular diseases across the globe.
ACE inhibitor is administered to control high blood pressure and are used for the treatment of various medical conditions such as hypertension, coronary artery disease, heart failure, diabetes, chronic kidney diseases, scleroderma, and migraine.
These enzymes relax the blood vessels as well as decrease blood flow, which leads to lower blood pressure, and decreases the oxygen demand from the heart. Benazepril, captopril, enalapril, cilazapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril are some of the ACE inhibitors used for treating hypertension.
Market Drivers, Restraints, Trends, and Opportunities
- Growing adoption of ACE Inhibitors in the management of chronic disorders is projected to drive the market growth.
- Increasing prevalence of hypertension and other cardiovascular disorders is driving the demand for ACE inhibitors.
- Rising demand for inexpensive drugs to manage medical complications related to heart is expected to have a positive impact on the growth of the global ACE inhibitors market.
- Side effects associated with the treatment, such as the increased risk of lung cancer can hamper the market growth.
Scope of the Report
The report on the global angiotensin converting enzyme (ACE) inhibitors market includes an assessment of the market, trends, segments and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Global Angiotensin Converting Enzyme (ACE) Inhibitors Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
| Forecast Years |
2021-2028 |
| Segmentation |
Types (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, and Phosphonate-containing Agents), and Applications (Hypertension, Cardiovascular Diseases, Kidney Diseases, and Others) |
|
Regional Scope |
North America, Latin America, Europe, Asia Pacific and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Bristol-Myers Squibb Company, Par Pharmaceutical Companies, Inc., UCB, Inc., Pfizer, Inc., AbbVie Inc., AstraZeneca, Bausch Health Companies, Inc., Novartis AG, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Silvergate Pharmaceuticals, Inc. |
Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Segment Insights
Sulfhydryl-containing agents segment to account a significant market share
Based on types, the ACE inhibitors market is segregated into sulfhydryl-containing agents, dicarboxylate-containing agents and phosphonate-containing Agents. The sulfhydryl-containing agents segment is anticipated to account for a considerable market share during the forecast period. On the other hand, the dicarboxylate-containing agents is expected to grow at a steady rate during the forecast period.
Diabetes segment is projected to expand at a high CAGR
Based on applications, the market is segregated into hypertension, cardiovascular diseases, kidney diseases, and others. The diabetes segment is expected to expand at a high CAGR during the forecast period. Rising cases of type 2 diabetes is driving the segment growth.
The cardiovascular diseases segment to account for a large market share during the forecast period. ACE inhibitors play a key role in the management of heart failure. Increasing prevalence of cardiovascular diseases is anticipated to spurn the segment growth. The hypertension segment is expected to hold a significant market share in the ACE inhibitors market. Primary hypertension is the prevalent form of hypertension, affecting about 95% of hypertensive patients. Rising incidence of hypertension is speculated to increase the demand for ACE inhibitors, driving the growth of the market segment.
North America is expected to dominate the market
Based on regions, the ACE inhibitors market is classified as, North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America is expected to dominate the market owing to rising prevalence of cardiovascular diseases and incidence of hypertension in the US and Canada.
The market in Asia Pacific is expected to exhibit a high CAGR during the forecast period. Rising population and swift development in the healthcare sector are driving the regional market growth. Additionally, increasing cases of cardiac diseases in countries such as India and China are expected to drive the growth of the market in the region. The market in Middle East and Africa is expected to expand at a moderate growth in the ACE inhibitors market due to limited access to advanced healthcare infrastructure.
Segments
Segments Covered in the ReportThe global angiotensin converting enzymes (ACE) inhibitors market has been segmented on the basis of
Types
- Sulfhydryl-containing Agents
- Dicarboxylate-containing Agents
- Phosphonate-containing Agents
- Hypertension
- Cardiovascular Diseases
- Kidney Diseases
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Bristol-Myers Squibb Company
- Par Pharmaceutical Companies, Inc.
- UCB, Inc.
- Pfizer, Inc.
- AbbVie, Inc.
- AstraZeneca
- Bausch Health Companies, Inc.
- Novartis AG
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Silvergate Pharmaceuticals, Inc.
Competitive Landscape
Major players of the market are Bristol-Myers Squibb Company, Par Pharmaceutical Companies, Inc., UCB, Inc., Pfizer, Inc., AbbVie Inc., AstraZeneca, Bausch Health Companies, Inc., Novartis AG, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Silvergate Pharmaceuticals, Inc.
Various major pharmaceutical companies are developing innovative products that are contributing to the growth of the market. For instance, in January 2017, Silvergate Pharmaceuticals, Inc. launched Epaned to tackle hypertension and heart failure. It was the first ready to use ACE inhibitor in oral solution form.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Angiotensin Converting Enzyme (ACE) Inhibitors Market - Supply Chain
4.5. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecast
4.5.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market Absolute $ Opportunity
5. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
5.3.1. Sulfhydryl-containing Agents
5.3.2. Dicarboxylate-containing Agents
5.3.3. Phosphonate-containing Agents
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
6.3.1. Hypertension
6.3.2. Cardiovascular Diseases
6.3.3. Kidney Diseases
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
8. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
8.4.1. Sulfhydryl-containing Agents
8.4.2. Dicarboxylate-containing Agents
8.4.3. Phosphonate-containing Agents
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
8.7.1. Hypertension
8.7.2. Cardiovascular Diseases
8.7.3. Kidney Diseases
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
9. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
9.4.1. Sulfhydryl-containing Agents
9.4.2. Dicarboxylate-containing Agents
9.4.3. Phosphonate-containing Agents
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
9.7.1. Hypertension
9.7.2. Cardiovascular Diseases
9.7.3. Kidney Diseases
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
10. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
10.4.1. Sulfhydryl-containing Agents
10.4.2. Dicarboxylate-containing Agents
10.4.3. Phosphonate-containing Agents
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
10.7.1. Hypertension
10.7.2. Cardiovascular Diseases
10.7.3. Kidney Diseases
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
11. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
11.4.1. Sulfhydryl-containing Agents
11.4.2. Dicarboxylate-containing Agents
11.4.3. Phosphonate-containing Agents
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
11.7.1. Hypertension
11.7.2. Cardiovascular Diseases
11.7.3. Kidney Diseases
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
12. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
12.4.1. Sulfhydryl-containing Agents
12.4.2. Dicarboxylate-containing Agents
12.4.3. Phosphonate-containing Agents
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
12.7.1. Hypertension
12.7.2. Cardiovascular Diseases
12.7.3. Kidney Diseases
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Market Share Analysis
13.2. Angiotensin Converting Enzyme (ACE) Inhibitors Distributors and Customers
13.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Bristol-Myers Squibb Company
13.4.2. Par Pharmaceutical Companies, Inc.
13.4.3. UCB, Inc.
13.4.4. Pfizer, Inc.
13.4.5. AbbVie, Inc.
13.4.6. AstraZeneca
13.4.7. Bausch Health Companies, Inc.
13.4.8. Novartis AG
13.4.9. Merck & Co., Inc.
13.4.10. Teva Pharmaceutical Industries Ltd.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Angiotensin Converting Enzyme (ACE) Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Angiotensin Converting Enzyme (ACE) Inhibitors Market - Supply Chain
4.5. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecast
4.5.1. Angiotensin Converting Enzyme (ACE) Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Angiotensin Converting Enzyme (ACE) Inhibitors Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market Absolute $ Opportunity
5. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
5.3.1. Sulfhydryl-containing Agents
5.3.2. Dicarboxylate-containing Agents
5.3.3. Phosphonate-containing Agents
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
6.3.1. Hypertension
6.3.2. Cardiovascular Diseases
6.3.3. Kidney Diseases
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
8. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
8.4.1. Sulfhydryl-containing Agents
8.4.2. Dicarboxylate-containing Agents
8.4.3. Phosphonate-containing Agents
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
8.7.1. Hypertension
8.7.2. Cardiovascular Diseases
8.7.3. Kidney Diseases
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
9. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
9.4.1. Sulfhydryl-containing Agents
9.4.2. Dicarboxylate-containing Agents
9.4.3. Phosphonate-containing Agents
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
9.7.1. Hypertension
9.7.2. Cardiovascular Diseases
9.7.3. Kidney Diseases
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
10. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
10.4.1. Sulfhydryl-containing Agents
10.4.2. Dicarboxylate-containing Agents
10.4.3. Phosphonate-containing Agents
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
10.7.1. Hypertension
10.7.2. Cardiovascular Diseases
10.7.3. Kidney Diseases
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
11. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
11.4.1. Sulfhydryl-containing Agents
11.4.2. Dicarboxylate-containing Agents
11.4.3. Phosphonate-containing Agents
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
11.7.1. Hypertension
11.7.2. Cardiovascular Diseases
11.7.3. Kidney Diseases
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
12. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Types
12.4.1. Sulfhydryl-containing Agents
12.4.2. Dicarboxylate-containing Agents
12.4.3. Phosphonate-containing Agents
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Market Size and Volume Forecast by Applications
12.7.1. Hypertension
12.7.2. Cardiovascular Diseases
12.7.3. Kidney Diseases
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Market Share Analysis
13.2. Angiotensin Converting Enzyme (ACE) Inhibitors Distributors and Customers
13.3. Angiotensin Converting Enzyme (ACE) Inhibitors Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Bristol-Myers Squibb Company
13.4.2. Par Pharmaceutical Companies, Inc.
13.4.3. UCB, Inc.
13.4.4. Pfizer, Inc.
13.4.5. AbbVie, Inc.
13.4.6. AstraZeneca
13.4.7. Bausch Health Companies, Inc.
13.4.8. Novartis AG
13.4.9. Merck & Co., Inc.
13.4.10. Teva Pharmaceutical Industries Ltd.
Segments Covered in the Report
The global angiotensin converting enzymes (ACE) inhibitors market has been segmented on the basis of
Types
The global angiotensin converting enzymes (ACE) inhibitors market has been segmented on the basis of
Types
- Sulfhydryl-containing Agents
- Dicarboxylate-containing Agents
- Phosphonate-containing Agents
- Hypertension
- Cardiovascular Diseases
- Kidney Diseases
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Bristol-Myers Squibb Company
- Par Pharmaceutical Companies, Inc.
- UCB, Inc.
- Pfizer, Inc.
- AbbVie, Inc.
- AstraZeneca
- Bausch Health Companies, Inc.
- Novartis AG
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Silvergate Pharmaceuticals, Inc.
Major players of the market are Bristol-Myers Squibb Company, Par Pharmaceutical Companies, Inc., UCB, Inc., Pfizer, Inc., AbbVie Inc., AstraZeneca, Bausch Health Companies, Inc., Novartis AG, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Silvergate Pharmaceuticals, Inc.
Various major pharmaceutical companies are developing innovative products that are contributing to the growth of the market. For instance, in January 2017, Silvergate Pharmaceuticals, Inc. launched Epaned to tackle hypertension and heart failure. It was the first ready to use ACE inhibitor in oral solution form.
Our Clients
Related Reports
Some other reports from this category!
